RxDoctor Payments Data

Kr Byju, MD

Gastroenterology · Sarasota, FLNPI 1649267972

Payments from drug & device makers

$9,990in general payments, 2019–2025

Across 382 payments — averaging $26.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Gilead$860
  • Takeda Pharmaceuticals U.S.A., Inc.$488
  • Pfizer$457
  • Regeneron Healthcare Solutions, Inc.$414
  • plus $5K from 38 others

What the payments were for

  • Speaking & faculty fees$2002%
  • Food & beverage$9,69497%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,990 in reported general payments places this provider in the 70th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$99,753
Medicare patients
376
Services billed
702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase35$121,147
ZenpepLipase/Protease/Amylase15$56,085
XifaxanRifaximin14$41,645
LinzessLinaclotide34$34,880
Mesalamine ErMesalamine28$6,878
Balsalazide Disodium12$1,989
Pantoprazole Sodium174$1,933
Cholestyramine LightCholestyramine21$1,809
Omeprazole117$1,217
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl41$718
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl44$590
Lactulose22$448
Famotidine18$368
Sucralfate14$306
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine12$301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,630$156,02769 claims
Aimmune Therapeutics, Inc.Zenpep$60$56,08515 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,148$41,64514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →